Similar to the US, Canada has a patent linkage system that requires generics to address certain patents before obtaining regulatory approval of drugs. Although in theory the two systems are similar, in practice there are nuances that make them different. Published in LMG Life Sciences, 2, pp. 153-154.
Article
The Same But Different: Patent Linkage in Canada
2013
Republication Requests
To obtain permission to republish this publication or any other publication, contact Erica Wirthlin at wirthline@bennettjones.com.
For Informational Purposes Only
This publication provides an overview of trends and legal updates for informational purposes only. For personalized legal advice, please contact the authors.
From the Same Authors
See AllBlog
Life Sciences Collaborations and the Risk of Joint Patent Infringement
May 26, 2026Emily P. Kettel & Vincent M. de Grandpré
Blog
Competition Tribunal Issues First-of-Its-Kind Decision in Private Abuse of Dominance Case Against Major Pharma Manufacturer
January 24, 2025Emrys Davis, Emily P. Kettel & Christina Skinner
Latest Insights
See All Insights See AllBlog
Ontario Court Reinforces Finality of Class Proceedings in Rejecting Late Opt-Out Request
July 17, 2026Ethan Z. Schiff & Evana Yukanna
Blog
No Standing Without Specifics: Alberta Court of Appeal Confirms that Cumulative Effects are no Substitute for Evidence
July 16, 2026Martin Ignasiak KC, Tyler McDonough & Logan Lazurko
Blog
C$10 Million Capital Gains Exemption Made Permanent for Employee Ownership Trusts
July 14, 2026 & 1 more



















